340B Purchases To Hit 8% Of Outpatient Brand Drug Sales In 2019 – White Paper
This article was originally published in The Pink Sheet Daily
Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.
You may also be interested in...
But biopharma industry can help drive reform of 340B discounts by emphasizing how it might improve pricing, Rep. Chris Collins, R-NY, suggests.
House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.